

Niercelkanker

DAG	TITEL	TIJD	LOCATIE
VRIJDAG 27.09.19	Frontline in mRCC: Ready to select treatment?	16.00 -17.30	Sevilla Auditorium (Hal 2)
<i>Pfizer sponsored symposium:</i>	Pfizer - Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>BMS sponsored symposium:</i>	Long-term experience and survival: an overview of I-O therapy in RCC and future research in GU cancers	18:00 -20:00	Bilbao Auditorium (Hal 5)
ZATERDAG 28.09.19	Treatment of the primary tumour in the metastatic setting	16.30 -18.00	Granada Auditorium (Hal 3)
ZONDAG 29.09.19	Specificity of upper tract urothelial carcinoma biology and management	08.45 -09.45	Cartagena Auditorium (Hal 3)
	ESMO Clinical Practice Guidelines 1	9.45 -11.45	Granada Auditorium (Hal 3)
<i>Pfizer/Merck sponsored symposium:</i>	GU 2.0 – Patient care in 2019 and beyond	13.00 -14.30	Tarragona Room (Hal 7)
	ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?	18:30 -20:00	Cordoba Auditorium (Hal 7)
MAANDAG 30.09.19	Selecting and sequencing therapy in previously untreated urothelial cancer	10.15 -11.45	Madrid Auditorium (Hal 2)
DINSDAG 01.10.19	Congress Highlights 1 – The best of ESMO 2019 – GU non-prostate	10.20 -10.40	Madrid Auditorium (Hal 2)

Niercelkanker

DAG	TITEL	TIJD	LOCATIE
VRIJDAG 27.09.19	Frontline in mRCC: Ready to select treatment?	16.00 -17.30	Sevilla Auditorium (Hal 2)
<i>Pfizer sponsored symposium:</i>	Pfizer - Real world data in oncology: It's growing role in research and patient care	18:00 -20:00	Alicante Auditorium (Hal 3)
<i>BMS sponsored symposium:</i>	Long-term experience and survival: an overview of I-O therapy in RCC and future research in GU cancers	18:00 -20:00	Bilbao Auditorium (Hal 5)
ZATERDAG 28.09.19	Treatment of the primary tumour in the metastatic setting	16.30 -18.00	Granada Auditorium (Hal 3)
ZONDAG 29.09.19	Specificity of upper tract urothelial carcinoma biology and management	08.45 -09.45	Cartagena Auditorium (Hal 3)
	ESMO Clinical Practice Guidelines 1	9.45 -11.45	Granada Auditorium (Hal 3)
<i>Pfizer/Merck sponsored symposium:</i>	GU 2.0 – Patient care in 2019 and beyond	13.00 -14.30	Tarragona Room (Hal 7)
	ESMO Colloquium supported by Ipsen - Metastatic clear cell renal cell carcinoma How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?	18:30 -20:00	Cordoba Auditorium (Hal 7)
MAANDAG 30.09.19	Selecting and sequencing therapy in previously untreated urothelial cancer	10.15 -11.45	Madrid Auditorium (Hal 2)
DINSDAG 01.10.19	Congress Highlights 1 – The best of ESMO 2019 – GU non-prostate	10.20 -10.40	Madrid Auditorium (Hal 2)

ESMO 2019 INDUSTRY SATELLITE SYMPOSIUM

GU 2.0 — PATIENT CARE IN 2019 AND BEYOND

Sunday 29 September 2019

13:00–14:30

Tarragona Auditorium, Hall 7,
Fira Gran Via,
Barcelona, Spain

INVITATION

Agenda

Chaired by Manuela Schmidinger, Medical University, Vienna, Austria

TIME	SESSION	SPEAKER
13:00–13:05	Introduction	Manuela Schmidinger Medical University, Vienna, Austria
13:05–13:25	The RCC patient journey	Manuela Schmidinger Medical University, Vienna, Austria
13:25–13:45	Looking to the future of RCC	Cristina Suarez Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain
13:45–14:10	Metastatic urothelial cancer – a landscape in transformation	Petros Grivas University of Washington, Fred Hutchinson Cancer Research Centre and Seattle Cancer Care Alliance, Seattle, USA
14:10–14:25	Audience Q&A	All – moderated by Chair
14:25–14:30	Conclusions	Manuela Schmidinger Medical University, Vienna, Austria

This satellite symposium is sponsored by the Merck-Pfizer Alliance

MERCK

